BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9193348)

  • 1. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial.
    Tempero M; Leichner P; Dalrymple G; Harrison K; Augustine S; Schlam J; Anderson J; Wisecarver J; Colcher D
    J Clin Oncol; 1997 Apr; 15(4):1518-28. PubMed ID: 9193348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
    Tempero M; Leichner P; Baranowska-Kortylewicz J; Harrison K; Augustine S; Schlom J; Anderson J; Wisecarver J; Colcher D
    Clin Cancer Res; 2000 Aug; 6(8):3095-102. PubMed ID: 10955789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
    Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
    Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
    J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
    Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L
    J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
    Mulligan T; Carrasquillo JA; Chung Y; Milenic DE; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
    Clin Cancer Res; 1995 Dec; 1(12):1447-54. PubMed ID: 9815943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
    Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
    J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49.
    Leichner PK; Akabani G; Colcher D; Harrison KA; Hawkins WG; Eckblade M; Baranowska-Kortylewicz J; Augustine SC; Wisecarver J; Tempero MA
    J Nucl Med; 1997 Apr; 38(4):512-6. PubMed ID: 9098192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma.
    Divgi CR; Scott AM; Gulec S; Broussard EK; Levy N; Young C; Capitelli P; Daghighian F; Williams JM; Finn RD
    Clin Cancer Res; 1995 Dec; 1(12):1503-10. PubMed ID: 9815950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma.
    Czuczman MS; Straus DJ; Divgi CR; Graham M; Garin-Chesa P; Finn R; Myers J; Old LJ; Larson SM; Scheinberg DA
    J Clin Oncol; 1993 Oct; 11(10):2021-9. PubMed ID: 8410126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.
    Hajjar G; Sharkey RM; Burton J; Zhang CH; Yeldell D; Matthies A; Alavi A; Losman MJ; Brenner A; Goldenberg DM
    Clin Colorectal Cancer; 2002 May; 2(1):31-42. PubMed ID: 12453334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
    Juweid M; Swayne LC; Sharkey RM; Dunn R; Rubin AD; Herskovic T; Goldenberg DM
    Gynecol Oncol; 1997 Dec; 67(3):259-71. PubMed ID: 9441773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics.
    Yu B; Carrasquillo J; Milenic D; Chung Y; Perentesis P; Feuerestein I; Eggensperger D; Qi CF; Paik C; Reynolds J; Grem J; Curt G; Siler K; Schlom J; Allegra C
    J Clin Oncol; 1996 Jun; 14(6):1798-809. PubMed ID: 8656248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.
    Forero A; Meredith RF; Khazaeli MB; Shen S; Grizzle WE; Carey D; Busby E; LoBuglio AF; Robert F
    Cancer Biother Radiopharm; 2005 Oct; 20(5):467-78. PubMed ID: 16248762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.
    Slovin SF; Scher HI; Divgi CR; Reuter V; Sgouros G; Moore M; Weingard K; Pettengall R; Imbriaco M; El-Shirbiny A; Finn R; Bronstein J; Brett C; Milenic D; Dnistrian A; Shapiro L; Schlom J; Larson SM
    Clin Cancer Res; 1998 Mar; 4(3):643-51. PubMed ID: 9533532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
    Chong G; Lee FT; Hopkins W; Tebbutt N; Cebon JS; Mountain AJ; Chappell B; Papenfuss A; Schleyer P; U P; Murphy R; Wirth V; Smyth FE; Potasz N; Poon A; Davis ID; Saunder T; O'keefe GJ; Burgess AW; Hoffman EW; Old LJ; Scott AM
    Clin Cancer Res; 2005 Jul; 11(13):4818-26. PubMed ID: 16000579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.
    Welt S; Divgi CR; Scott AM; Garin-Chesa P; Finn RD; Graham M; Carswell EA; Cohen A; Larson SM; Old LJ
    J Clin Oncol; 1994 Jun; 12(6):1193-203. PubMed ID: 8201382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.